8-K: Centessa Q3 2025: Orexin Agonists Show Strong Phase 2a Data

Centessa Pharmaceuticals announced its Q3 2025 financial results and positive Phase 2a data for its lead Orexin Receptor 2 (OX2R) agonist, ORX750, for narcolepsy and idiopathic hypersomnia.

Summary

• Centessa Pharmaceuticals reported its financial results for the third quarter ended September 30, 2025.
• Positive Phase 2a data for ORX750 in initial dosing cohorts for Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) were announced.
• ORX750 demonstrated statistically significant, clinically meaningful, and dose-dependent improvements across key measures including the Maintenance of Wakefulness Test (MWT), Epworth Sleepiness Scale (ESS), and Weekly Cataplexy Rate (WCR).
• A generally favorable safety and tolerability profile was observed for ORX750 across all doses tested.
• The company expects to initiate the registrational program for ORX750 in Q1 2026.
• Phase 1 data for ORX142 in healthy volunteers showed a highly differentiated profile with high potency, selectivity, rapid onset, and favorable safety; patient studies are expected to begin in Q1 2026.
• ORX489 is advancing in IND-enabling studies, with clinical studies planned for Q1 2026, subject to IND clearance.
• Cash, cash equivalents, and investments totaled $349.0 million as of September 30, 2025, projected to fund operations into mid-2027.
• Net loss for Q3 2025 was $54.9 million, an increase from $42.6 million for Q3 2024.
• Research & Development (R&D) expenses increased to $41.6 million for Q3 2025 from $33.9 million for Q3 2024.
• General & Administrative (G&A) expenses slightly decreased to $12.2 million for Q3 2025 from $12.5 million for Q3 2024.

Sentiment

Score: 8

Explanation: The filing presents very strong positive clinical data for its lead drug candidates, particularly ORX750, which shows potential for best-in-class efficacy and a favorable safety profile across multiple indications. The advancement of two other promising candidates and a solid cash runway into mid-2027 further bolster confidence. While the net loss increased, this is typical for a clinical-stage biotech investing heavily in R&D, and the positive clinical outcomes outweigh this in terms of future potential.

Positives

• ORX750 Phase 2a data demonstrated statistically significant, clinically meaningful, and dose-dependent improvements in MWT, ESS, and WCR across NT1, NT2, and IH.
• ORX750 showed a generally favorable safety and tolerability profile with all treatment-emergent adverse events (TEAEs) being transient and mild to moderate in severity.
• ORX750 achieved a >20-minute change from baseline in mean sleep latency on the MWT for NT1 (1.5 mg cohort) and >10-minute change for NT2 (4.0 mg cohort).
• ORX750 achieved an 87% relative reduction in Weekly Cataplexy Rate for NT1 (1.5 mg cohort).
• ORX750 achieved normative range ESS scores for NT1 (1.5 mg cohort, mean ESS 5.1) and NT2 (4.0 mg cohort, mean ESS 8.1).
• ORX750 is positioned as a potential best-in-class OX2R agonist for NT1, NT2, and IH, and potentially the first OX2R agonist to treat NT2 and IH.
• ORX142 Phase 1 data in healthy volunteers demonstrated a highly differentiated profile characterized by high potency, selectivity, rapid onset of action, differentiated pharmacokinetics (PK), and a generally favorable safety and tolerability profile.
• The company has a strong cash position of $349.0 million as of September 30, 2025, providing an estimated cash runway into mid-2027.
• Multiple OX2R agonist candidates (ORX750, ORX142, ORX489) are advancing with robust clinical milestones anticipated in Q1 2026, establishing leadership in this emerging class.

Negatives

• Net loss increased to $54.9 million for the third quarter ended September 30, 2025, compared to $42.6 million for the same period in 2024.
• Research & Development (R&D) expenses increased to $41.6 million for Q3 2025, up from $33.9 million for Q3 2024, reflecting higher development costs.
• Total cash, cash equivalents, and investments decreased from approximately $482.2 million as of December 31, 2024, to $349.0 million as of September 30, 2025.

Risks

• Risks related to the safety, tolerability, and efficacy profile of product candidates including ORX750, ORX142, and ORX489.
• The company's ability to identify, screen, recruit, and retain a sufficient number of participants in its existing and anticipated new studies or clinical trials within anticipated timelines.
• Uncertainty regarding the predicted efficacious doses of each of ORX750, ORX142, and ORX489.
• The company's ability to successfully conduct its clinical development of ORX750, ORX142, and ORX489.
• The ability to prosecute, protect, and maintain the company's intellectual property position.
• Business (including commercial viability), regulatory, economic, and competitive risks, uncertainties, contingencies, and assumptions about the company.
• Risks inherent in developing product candidates and technologies.
• Future results from ongoing and planned clinical trials may not be predictive of future results in ongoing or future studies.
• The company's ability to obtain adequate financing to fund planned clinical trials and other expenses.
• Trends in the industry and the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing.
• The risk that any one or more of the company's product candidates will not be successfully developed and/or commercialized.
• Economic risks to the United States and United Kingdom banking systems.
• Geo-political risks such as the Russia-Ukraine war or the Middle East conflicts or trade wars.

Future Outlook

Centessa Pharmaceuticals anticipates a robust series of clinical milestones in Q1 2026, including the initiation of the registrational program for ORX750, patient studies for ORX142, and clinical studies for ORX489 (subject to IND clearance). The company expects its current cash, cash equivalents, and investments of $349.0 million as of September 30, 2025, to fund operations into mid-2027.

Management Comments

• Saurabh Saha MD PhD, Chief Executive Officer: "We are thrilled to share significant progress marked by clinical data from our growing OX2R agonist program. Based on today's update, ORX750 continues to stand out as a potential best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, and potentially as the first OX2R agonist to treat NT2 and IH."
• Saurabh Saha MD PhD, Chief Executive Officer: "We are equally excited by the progress of ORX142, where Phase 1 data in healthy volunteers demonstrated a highly differentiated profile... With multiple differentiated orexin agonists advancing, we believe we are establishing clear leadership in this emerging class and building a durable, long-term growth platform in neuroscience."
• Mario Alberto-Accardi PhD, President, Centessa Orexin Program: "In these early cohorts, ORX750 has already achieved notable improvements on MWT, ESS and WCRkey measures of symptom normalization in NT1translating clinical efficacy into meaningful, real-world gains in wakefulness and daily functioning."
• Mario Alberto-Accardi PhD, President, Centessa Orexin Program: "ORX750 also achieved clinically meaningful wake promotion in NT2 with observed improvements to date that could potentially establish ORX750 as the new standard of care in NT2. And, for IH, ORX750 is the first OX2R agonist to demonstrate statistically significant and clinically meaningful improvements on multiple efficacy measures including on the MWT."

Industry Context

The announcement positions Centessa Pharmaceuticals as a leader in the emerging class of Orexin Receptor 2 (OX2R) agonists, which are gaining recognition for their potential to transform the standard of care for sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders. The company's focus on narcolepsy (NT1, NT2) and idiopathic hypersomnia (IH) addresses large patient populations with significant unmet medical needs, where current therapies have notable limitations. By advancing multiple differentiated orexin agonists, Centessa aims to establish a durable, long-term growth platform in neuroscience, capitalizing on the broad therapeutic potential of targeting the orexin pathway.

Comparison to Industry Standards

• ORX750 is presented as a potential best-in-class OX2R agonist for NT1, NT2, and IH, and potentially the first OX2R agonist to treat NT2 and IH, suggesting a superior profile compared to existing treatments.
• Current approved therapies for narcolepsy and IH are noted to have significant limitations, including only slightly increased sleep onset latencies as measured by MWT, inadequate addressing of excessive daytime sleepiness (EDS), cataplexy, or brain fog, potential for significant side effects leading to treatment discontinuations, and challenges with complex medication regimens.
• ORX750's demonstrated efficacy, such as a >20-minute change from baseline in mean sleep latency on the MWT for NT1 and an 87% relative reduction in Weekly Cataplexy Rate for NT1, along with achieving normative range ESS scores, suggests a more comprehensive and effective treatment compared to the suboptimal efficacy and poor tolerability of current standard of care therapies.
• The filing highlights that ORX750's distinct PK profile contributes to generally favorable safety and tolerability, along with a prolonged duration of action, which could differentiate it from other treatments.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potential for future drug approvals, and extended cash runway. Increased R&D expenses and net loss are typical for a growth-stage biotech but could be a concern if clinical progress falters.
• Patients (NT1, NT2, IH): Highly positive impact as ORX750 shows potential to be a best-in-class treatment, offering significant improvements in wakefulness and daily functioning with a favorable safety profile, addressing high unmet medical needs.
• Employees: Positive outlook due to strong pipeline progress and continued investment in R&D, suggesting job stability and growth opportunities.
• Regulatory Authorities: The positive clinical data will be crucial for future regulatory submissions and discussions.

Next Steps

• Initiate registrational program for ORX750 in Q1 2026.
• Initiate patient studies for ORX142 in Q1 2026.
• Obtain IND clearance and initiate clinical studies for ORX489 in Q1 2026.
• Continue dose escalation for ORX750 in ongoing Phase 2a cohorts with both once-daily and split-dose regimens.
• Participants in the CRYSTAL-1 study may enroll into an ongoing 9-week open-label long-term extension (LTE) of ORX750.

Key Dates

Recommendation

The clinical data for ORX750 is exceptionally strong, demonstrating statistically significant and clinically meaningful improvements across all three target indications (NT1, NT2, IH) with a favorable safety profile. This positions ORX750 as a potential best-in-class and first-in-class treatment for NT2 and IH, addressing a large market with high unmet needs. The rapid advancement of two other promising OX2R agonists (ORX142 and ORX489) further de-risks the pipeline and establishes Centessa as a leader in this emerging therapeutic area. The company's cash runway into mid-2027 provides sufficient funding for these critical development milestones. While the net loss increased, this is expected for a clinical-stage biotech with significant R&D investment, and the overwhelmingly positive clinical results suggest substantial future value creation.

Keywords

Centessa Pharmaceuticals, CNTA, Orexin, OX2R agonist, Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia, NT1, NT2, IH, ORX750, ORX142, ORX489, Clinical Trials, Phase 2a, Phase 1, Neuroscience, Sleep Disorders, Pharmaceutical, Biotech, Drug Development, Q3 2025 Earnings